TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth  in vitro  and  in vivo

Jing Wu; Shuang Li; Yang Yang; Shan Zhu; Mingyou Zhang; Yuan Qiao; Yong-Jun Liu; Jingtao Chen

doi:10.18632/oncotarget.14315

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo

Jing Wu _, Shuang Li, Yang Yang, Shan Zhu, Mingyou Zhang, Yuan Qiao, Yong-Jun Liu and Jingtao Chen

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:11708-11718. https://doi.org/10.18632/oncotarget.14315

Metrics: PDF 2767 views | HTML 3438 views | ?

Abstract

Jing Wu1, Shuang Li1, Yang Yang1, Shan Zhu1, Mingyou Zhang2, Yuan Qiao1, Yong-Jun Liu1,3, Jingtao Chen1

1Institute of Translational Medicine, The First Hospital, Jilin University, Changchun, 130061, China

2Department of Cardiovascular Center, The First Hospital, Jilin University, Changchun, 130031, China

3Sanofi Research and Development, Cambridge, MA, 02139, USA

Correspondence to:

Jingtao Chen, email: [email protected]

Keywords: breast cancer, plasmacytoid dendritic cells, Toll-like receptor, Imiquimod, CpG

Received: May 10, 2016 Accepted: December 05, 2016 Published: December 28, 2016

ABSTRACT

Plasmacytoid dendritic cells (pDCs) are a unique subset of naturally occurring dendritic cells, which triggers the production of large amounts of type I interferons (IFNs) after viral infections through Toll-like receptor (TLR) 7 and TLR9. Recent studies have demonstrated that the activation of pDCs kills melanoma cells. However, the role of activated pDCs in breast cancer remains to be determined. In the present study, we generated mouse models of breast cancer and demonstrated that activated pDCs can directly kill breast tumor cells through TRAIL and Granzyme B. Furthermore, we established that pDCs initiate the sequential activation of NK cells and CD8⁺ T cells, and ultimately inhibit breast tumor growth. Understanding the role of activated pDCs in breast cancer may help to develop new strategies for manipulating the function of pDCs and induce anti-tumor immunity in breast cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14315

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo

Abstract